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We investigated the relationship of the presence of anti-
bodies to HTLV-III and immunologic abnormalities in 
patients with hemophilia. Serum antibodies to HTLV-
III were analyzed by ELISA assay, immunoprecipita-
tion of labeled cell extracts, and immunoprecipitation 
of purified HTLV-III p24. Thirty-four (61%) of the total 
group (n = 56) had antibody to HTLV-III; 34 (76%) of 
45 patients given commercial factor VIII preparations 
were seropositive, compared with none of 11 patients 
treated exclusively with cryoprecipitate obtained from 
volunteer blood donors. Of patients who were sero-
positive for HTLV-III antibody, 94% had abnormal T4/
T8 ratios, and 33% of those whose serum was antibody 
negative had abnormal T4/T8 ratios; five patients, each 
antibody positive, have lymphadenopathy syndrome. 
Sequential studies in a subset of patients indicate that 
there is a changing pattern of antibody production to 
HTLV-III antigens after seroconversion.
Prior to reports linking human T cell lymphotropic virus 
type III1,2 or lymphadenopathy-associated virus3,4 with 
acquired immune deficiency syndrome, we5 and others6, 
7 described laboratory abnormalities of immune regula-
tion, particularly lymphocyte subset alteration, in asymp-
tomatic patients with hemophilia. Subsequently, throm-
bocytopenia, lymphadenopathy syndrome, and other 
AIDS-related abnormalities were noted in hemophilic 
patients.8-10 Furthermore, hemophilic patients given con-
centrates from the United States have been found to have 
a high prevalence of antibody to LAV/HTLV-III,4,11-15 
and the appearance of antibody appears to eoincide with 
the AIDS epidemic. To determine whether the immuno-
logic abnor malities are associated with evidence of in-
fection or exposure to the retrovirus, we investigated the 
presence of serum antibody to one of the isolates, HTLV-
III, in patients with hemophilia.
See related article, p. 504, and letter, p. 631. 
AIDS Acquired immune deficiency syndrome
HTLV-III Human T cell lymphotropic virus type III
ELISA Enzyme-linked immunosorbent assay
LAV Lymphadenopathy-associated virus
SDS-PAGE Sodium dodecylsulfate-polyacrylamide 
 gel electrophoresis
METHODS
All patients enrolled in the comprehensive care pro-
gram of the Great Lakes Hemophilia Foundation who 
live within a 60-mile radius of Milwaukee were contacted 
to participate in the study; 43 patients were selected on
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the basis of availability to have a sample of blood taken 
during the 2-week period of sampling. Thirteen addi-
tional patients were selected from the Green Bay sat-
ellite center when they were evaluated for other rea-
sons during the same period. The patients were divided 
into two groups, those in whom hemorrhages were 
treated with commercial lyophilized concentrate and 
those exclusively given cryoprecipitate prepared from 
the plasma of volunteer blood donors at the Blood Cen-
ter of Southeastern Wisconsin. Histories were obtained 
from all patients, and all were specifically examined 
for the presence of lymphadenopathy and hepatosple-
nomegaly. Control groups included normal adults, 15 
parents of hemophilic boys, five spouses of hemophilic 
men, and 50 homosexual men seen at a Milwaukee com-
munity medical clinic.
Clinical laboratory studies. Complete blood counts 
and platelet counts were performed on an ELT-8DS Blood 
Analyzer (Ortho Diagnostic Systems, Westwood, Mass.). 
White blood cell differential counts were performed by 
visualization of cells on a Wright-stained blood smear. 
Serum IgG, IgM, and IgA concentrations were deter-
mined by radial immunodiffusion (Helena Laboratories, 
Beaumont, Texas). Enumeration of lymphocyte subsets 
was determined by indirect immunofluorescence with 
OKT monoclonal antibodies incubated with the Ficoll-
Hypaque separated mononuclear cell preparation from 
venous blood, as previously described.5
Virus and cells. Uninfected HT-9 cells and HT-9 cells 
chronically infected with HTLV-III were kindly provided 
by R. C. Gallo, National Cancer Institute, Bethesda, Mary-
land. Virus was concentrated one thousandfold, purified 
by density gradient centrifugation, and disrupted by 
sonication in the presence of 1% Triton X-100 and 0.05 M 
Tris-HCl (pH 9.0). The solution of disrupted virus was 
clarified by centrifugation at 100,000 × g for 1 hour.
HTLV-III ELISA. In brief, the assay was performed 
by incubation of test sera with solubilized HTLV-III 
antigen bound to wells of microtiter plates or antigen-
coated polystyrene beads (Abbott Laboratories, North 
Chicago, Illinois). After washing the plates or beads, al-
kaline phosphatase-conjugated goat anti-human IgG 
was added, and after further washing the substrate p-
nitrophenyl phosphate was used to quantitate the an-
tibody bound.
Immunoprecipitation of labeled cell extracts. Cul-
tures of 107 HT -9 cells and 107 HT-9 cells chronically 
infected with HTLV-III were centrifuged and washed 
twice in methionine- and cysteine-free medium, resus-
pended in 10 ml of the same medium, and allowed to 
incubate at 37° C for 30 minutes. Cells were then col-
lected by centrifugation and placed in 10 ml of me-
dium containing 100 μCi/ml 35-S methionine and 100 
μCi/ml 35-S cysteine. Cells were incubated for 4 hours 
at 37° C in this medium, harvested by centrifugation, 
and washed twice in complete media. Cells were resus-
pended in lysis buffer containing 10 mM sodium phos-
phate, pH 7.5, 100 mM NaCl, 1% Triton X-100, 0.5% so-
dium deoxycholate, and 0.1% sodium dodecyl sulfate 
at a concentration of 4 X 106 cells/ml. Ten microliters of 
test serum was incubated with 200 μl aliquots of lysate 
for 30 minutes at 0° C; Staphylococcus aureus protein A 
bound to Sepharose beads (Pharrnacia, Piscataway, 
N.J.) was then used to recover antigen-antibody com-
plexes, which were then analyzed by SDS-PAGE as pre-
viously described.17
p-24 Radioimmunoassay. Double-antibody precip-
itation with 125I-labeled HTLV-III p24 was performed 
as previously described.18 In brief, the p24 protein was 
purified to homogeneity by phosphocellulose column 
chromatography18 and labeled with 125I (30 μCi/μg) by 
Iodo-beads (Pierce Chemical Co., Rockford, Ill.). Serial 
dilutions of test sera were incubated with 125I-labeled pu-
rified p24, followed by precipitation of antigen-antibody 
complexes by incubation with anti-human IgG antisera, 
centrifugation to recover precipitates, and counting in an 
ANSA gamma counter (Abbott Laboratories). A sample 
was considered positive if precipitated counts were five 
times background.
RESULTS
Antibody to HTLV-III was detected by ELISA in 34 
(61%) of 56 hemophilic patients (Table I). Among 45 pa-
tients who received commercial lyophilized concentrate, 
34 (76%) had antibody to HTLV-III, compared with none 
of 11 patients treated exclusively with cryoprecipitate. 
Neither of the two patients with hemophilia B treated 
with factor IX concentrate had antibody, but three of four 
patients with inhibitors to factor VIII, all treated with 
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both factor VIII and factor IX concentrate, had antibody.
All patients with positive results by ELISA had anti-
body to viral glycoproteins gp120 and gp 160, as demon-
strated by radioimmunoprecipitation of labeled cell ex-
tracts (Figure 1). Similarly, all patients who had positive 
ELISA results had antibodies capable of recognizing 125I-
labeled HTLV-III p24; however, titers of these anti-p24 
antibodies varied as much as a thousandfold. Those with 
low antibody titers to purified p24 also lacked detection 
of anti-p24 by radioimmunoprecipitation of labeled cell 
extracts. Furthermore, the ability of these sera to precipi-
tate pp55 varied (Figure 1). This result is not unexpected, 
because pp55 is a percursor protein consisting of the p24, 
p17, and pl S gag proteins of the virus. Thus, sera with a 
low titer to p24 may be unable to precipitate quantities of 
pp55 if antibodies to other gag proteins are not present.
Chi-square analysis of immunologic status and HTLV-
III serology revealed five statistically significant factors 
(Table II). Each of five patients with persistent gener-
alized lymphadenopathy had HTLV-III antibody. De-
creased platelet counts, decreased T4 lymphocytes, 
decreased T4/T8 ratios, and elevated serum IgG con-
centrations were associated with antibody to HTLV-III, 
whereas abnormal IgM and IgA and elevated T8 lym-
phocytes were not associated with HTLV-III antibodies.
Sequential studies were performed on samples stored 
since January 1982 from 17 of the patients who were se-
ropositive for HTLV-III; only three had results on ear-
lier samples. In November 1982, patient 1 was serone-
gative for HTLV-III antibody and had a normal T4/T8 
ratio. Two months later, antibody was detectable and his 
T4/T8 ratio decreased. Antibody and T4/T8 ratio have 
remained abnormal, and in May 1984, 17 months after 
the apperance of HTLV-III antibodies, persistent lymph-
adenopathy developed. Patient 2 had a similar course, 
with seroconversion in October 1982, a decrease in T4/
T8 ratio at his next evaluation, and development of gen-
eralized lymphadenopathy 22 months later. After the ap-
pearance of antibody to HTLV-III in January 1983, a third 
patient developed an abnormal T4/T8 ratio in Novem-
ber 1983, and had an episode of localized herpes zoster 
in February 1985.
The pattern in these three patients of serum reactivity to 
various HTLV-III viral proteins by immune precipitation 
of HTLV-III proteins is demonstrated in Figure 2. None 
of the initial samples precipitated viral proteins, whereas 
all three precipitated the gp 160-120, pp55, and p24 vi-
ral proteins when studied most recently. The patients
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with lymphadenopathy precipitated relatively more 
pp55 and p24 than did the patient with herpes zoster. In 
contrast, a fourth patient, initially seropositive at the on-
set of the study, had an early response to p24, which was 
absent 18 months later; lymphadenopathy also has and 
more recently the onset of significant thrombocytopenia 
(platelet count <50,000/μl).
Selected family members were examined to some in-
sight into the transmissibility of HTLV-III. Fifteen par-
ents of hemophilic boys (the sons of 10 were seropositive 
for HTLV-III antibody) who prepared and administered 
treatment product were seronegative for HTLV-III anti-
body. Similarly, none of five spouses of hemophilic pa-
tients (two positive for HTLV-III antibody) had HTLV-
III antibody. In contrast, 14 (28%) of 50 homosexual men 
seen at a community medical clinic in Milwaukee were 
seropositive for HTLV-III by ELISA.
DISCUSSION
Evidence for a human retroviral cause for AIDS has re-
cently accumulated. The original isolates, HTLV-III and 
LAV, are likely the same virus19 and have been cultured 
from blood, semen, and saliva from patients with AIDS 
or lymphadenopathy syndrome and from asymptomatic 
individuals from high-risk groups. 1,3,4,11,20-27 Antibody 
to these viruses has been detected in the serum of 
both asymptomatic and ill individuals from these risk 
groups.1,3,4,12-16 Antibody to HTLV-III/LAV has been de-
tected in 34%11 to 94%12 asymptomatic hemophilic pa-
tients, a group at high risk for AIDS. In this study, 61% 
of hemophilic patients had evidence of prior exposure to 
HTLV-III/LAV. It is not known whether antibody sero-
conversion occurred in response to exposure to live virus 
and reflects or resolved infection, or resulted from expo-
sure to inactivated virus in clotting factor replacement 
products. However, the presence of lymphadenopathy 
syndrome, thrombocytopenia, herpes zoster, and labo-
ratory evidence of immune dysregulation similar to that 
associated with AIDS suggests that these patients have 
been exposed to live virus. Inasmuch as none of these pa-
tients has developed the full clinical symptoms of AIDS, 
and may have future resolution rather than progression 
of immunologic dysfunction, any speculation regarding 
the protective nature of various antibody patterns would 
be premature. Nevertheless, whereas only 4% of anti-
body-positive patients have normal T4/T8 ratios, 33% of 
antibody-negative patients have abnormal T4/T8 ratios 
(Table II). This implies that a spectrum of in vitro labo-
ratory abnormalities, associated with factor VIII concen-
trate therapy, occurs independent of HTLV-III antibody 
positivity. In the light of evidence suggesting that anti-
genemia can exist in asymptomatic antibody-negative 
individuals,26 this interpretation is somewhat tentative 
pending the availability of antigen testing.
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HTLV-III/LAV appears to be transmitted by intimate 
sexual contact and by exposure to blood products, and 
not by casual contact such as typical exposure to family 
members other than spouses. None of the parents of he-
mophilic patients tested had antibody to HTLV-III. The 
five spouses of hemophilic patients (two antibody posi-
tive) reported had negative HTLV-III serologic findings. 
However, continued follow-up of this group is needed 
so that accurate counseling can be provided in the fu-
ture; evidence for infection with HTLV-III via heterosex-
ual transmission is now emerging.28-30
Hemophilic patients given nonheated commercial fac-
tor VIII concentrates are at high risk for development of 
antibody to HTLV-III and associated immunologic ab-
normalities. Patients given cryoprecipitate prepared from 
the plasma of Southeastern Wisconsin blood donors ap-
pear to be at lower risk. Preliminary evidence suggests 
that heat treatment of clotting factor concentrates signifi-
cantly reduces retrovirus infectivity,31-32 nonheated con-
centrates should not be used for treatment of in patients 
with hemophilia.
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